294878-00-5

Basic information

• Product Name: 2-BenzofurancarboxaMide, 3-aMino-5-chloro-
• Synonyms: 2-BenzofurancarboxaMide, 3-aMino-5-chloro-;2-BenzofurancarboxaMide;3-amino-5-chlorobenzofuran-2-carboxamide
• CAS NO: 294878-00-5
• Molecular Formula: C₉H₇ClN₂O₂
• Molecular Weight: 210.61708
• Mol File: 294878-00-5.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-BenzofurancarboxaMide, 3-aMino-5-chloro-(CAS DataBase Reference)
• NIST Chemistry Reference: 2-BenzofurancarboxaMide, 3-aMino-5-chloro-(294878-00-5)
• EPA Substance Registry System: 2-BenzofurancarboxaMide, 3-aMino-5-chloro-(294878-00-5)

Safety Data

• Hazardous Substances Data: 294878-00-5(Hazardous Substances Data)

Usage

Chemical Class

Benzofuran carboxamides

Structure

Contains a benzofuran ring: A heterocyclic compound with a furan ring fused to a benzene ring.
Substituents:
Amino group (NH2) at the 3-position of the benzofuran ring.
Chlorine atom (Cl) at the 5-position of the benzofuran ring.

Utility

Research and pharmaceutical applications:
It serves as a building block or starting material for the synthesis of other compounds.
Potential for specific biological or pharmacological activities, prompting further study.

Safety Considerations

Proper handling and safety precautions must be observed when working with 2-Benzofurancarboxamide, 3-amino-5-chloro-.

Upstream product

• 887281-48-3 3-amino-5-chlorobenzofuran-2-carbonitrile 
• 894796-29-3 3-amino-5-chlorobenzofuran-2-carboxylic acid 
• 7664-41-7 ammonia 
• 1169561-46-9 C₉H₇ClN₂O₂ 
• 13589-72-5 5-chloro-2-hydroxybenzonitrile 

Downstream Products

• 1169549-65-8 8-chloro-2-(2-chlorophenyl)[1]benzofuro[3,2-d]pyrimidin-4(3H)-one 
• 1169558-38-6 XL413 

Relevant articles and documents

Discovery of XL413, a potent and selective CDC7 inhibitor

CDC7 is a serine/threonine kinase that has been shown to be required for the initiation and maintenance of DNA replication. Up-regulation of CDC7 is detected in multiple tumor cell lines, with inhibition of CDC7 resulting in cell cycle arrest. In this paper, we disclose the discovery of a potent and selective CDC7 inhibitor, XL413 (14), which was advanced into Phase 1 clinical trials. Starting from advanced lead 3, described in a preceding communication, we optimized the CDC7 potency and selectivity to demonstrate in vitro CDC7 dependent cell cycle arrest and in vivo tumor growth inhibition in a Colo-205 xenograft model.

BENZOFUROPYRIMIDINONES AS PROTEIN KINASE INHIBITORS

A compound according to formula I: or a pharmaceutically acceptable salt thereof; wherein R1, R2, R3a, R3b, R3c and R3d are as defined in the specification, pharmaceutical compositions thereof, and methods of use thereof.

NOVEL BENZOFURAN DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND USES OF THESE

[From equivalent EP1710233A1] The present invention provides compounds represented by general formula (I): or pharmaceutical acceptable salts thereof, wherein R1 is hydrogen or lower alkyl; R2 is lower alkyl, halo-lower alkyl, cycloalkyl, heterocycloalkyl, aryl, aralkyl, arylalkenyl, aryloxy-lower alkyl, heteroaryl, heteroaryl-lower alkyl, etc; R3, R4, R5 and R6 are each hydrogen, halogen, cyano, lower alkyl, halo-lower alkyl, lower alkoxy, hydroxy, aryl, etc; provided that at least one of R3, R4, R5 and R6 is other than hydrogen. Compound (I) of the present invention shows a potent adenosine A2A receptor antagonistic activity, and are useful for treating or preventing a disease mediated by adenosine A2A receptors such as motor function disorders, depression, anxiety disorders, cognitive function disorders, cerebral ischemia disorders, restless legs syndrome and the like.